No increased cancer risk with glargine versus human insulin

August 6, 2013
No increased cancer risk with glargine versus human insulin
There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn insulin, according to a study published online July 22 in Diabetes Care.

(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study published online July 22 in Diabetes Care.

Til Stürmer, M.D., Ph.D., from the University of North Carolina at Chapel Hill, and colleagues compared evidence on the long-term effects of glargine versus NPH insulin on the risk of cancer using data from the Inovalon MORE² Registry from January 2003 to December 2010. Initiators of glargine and human NPH without an insulin prescription during the prior 19 months were identified, and balanced on risk factors for cancer outcomes based on comorbidities, comedication, and health care use during the previous 12 months.

The researchers found that more patients initiated glargine than NPH (43,306 and 9,147 patients, respectively). Over 1.2 years of follow-up, 993 initiators of glargine developed cancer, while during 1.1 years of follow-up, 178 of those taking NPH developed cancer, for an overall hazard ratio of 1.12 for glargine initiators (95 percent confidence interval, 0.95 to 1.32). For all types of cancer (breast, prostate, and ) and various durations of treatment, as well in all sensitivity analyses, the results were consistent.

"Patients initiating rather than NPH do not seem to be at an increased risk for cancer," the authors write.

Several authors disclosed to pharmaceutical companies, including Sanofi, which funded the study.

Explore further: Insulin glargine's main metabolic effect as metabolite M1

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

Recommended for you

Unique molecular atlas of pancreas produced

September 23, 2016

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between ...

Can long naps cause diabetes?

September 14, 2016

A study presented at a scientific congress Thursday reported a link between long naps and a higher risk of diabetes, though it couldn't say if daytime sleeping was a symptom or a cause.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.